Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112174 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Nan Zhong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, China. Hauptthemen laut MEDLINE: Antigens, CD19, Cytomegalovirus Infections, Immunotherapy, Adoptive, Lymphoma, Follicular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
CD19-directed chimeric antigen receptor (CAR) T cell therapy has been shown to achieve a considerably durable response in patients with refractory or relapsed B cell non-Hodgkin lymphomas. Most of these CARs were generated by lentivirus. With the exception of Yescarta and Tecartus, few patients with relapsed-/refractory- lymphoma have been treated clinically with a CARs using retroviral vector (RV). Here, we reported a relapsed/refractory grade 2 follicular lymphoma patient with multiple chemotherapy failures, and was treated with a novel CD19 CAR-T cell manufactured from a RV. After tumor burden was reduced with Obinutuzumab and Duvelisib, the patient was infused novel CD19 CAR-T cells at a dose of 3 × 106 cells/ kg. Then he experienced a rapid response and achieved almost complete remission by day 26. Only grade 2 CRS, bilateral submaxillary lymph node enlargement and cytomegalovirus (CMV) infection occurred without neurotoxicity, and the patient's condition improved after a series of symptomatic treatments. In addition, CAR copy number peaked at 532,350 copies/μg on day 15 and continued to expand for 5 months. This may be the first case report of RV preparation of novel CD19 CAR-T cells for direct treatment of recurrent follicular lymphoma. We will observe its long-term efficacy and conduct trials in more patients in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, China.
- Shenzhen Cell Valley Biomedical Co., LTD, Shenzhen 518118, China.
- Shenzhen Cell Valley Biomedical Co., LTD, Shenzhen 518118, China. Electronic address: jw@sz-cell.com.
- Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, China. Electronic address: llqwsp@hotmail.com.
- Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, China. Electronic address: guozhi77@126.com.
Zitieren
APA
Zhong, N., Ma, Q., Gong, S., Shi, Y., Zhao, L., Wang, D., Zhou, H., Liu, N., Ye, Y., Wang, J., Liu, L., & Guo, Z. (2024). Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112174
Vancouver
Zhong N, Ma Q, Gong S, Shi Y, Zhao L, Wang D, et al. Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112174
BibTeX
@article{Zhong2024,
author = {Zhong, Nan and Ma, Qihong and Gong, Shiting and Shi, Yuanyuan and Zhao, Lijun and Wang, Danyu and Zhou, Huanhuan and Liu, Ning and Ye, Yuan and Wang, Jianxun and Liu, Liqiong and Guo, Zhi},
title = {Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112174}
}
EUVIMED